Specific protein degradation is being explored in its place approach in cancer, whereby the natural protein degradation program is co-opted for therapeutic purposes. Lately made novel molecules termed proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. Just one ligand binds towards the ‘protein of interest’ https://www.directivepublications.org/journal-of-clinical-breast-cancer/